SG11202109118XA - Anti-cd6 antibody compositions and methods for treating lupus - Google Patents
Anti-cd6 antibody compositions and methods for treating lupusInfo
- Publication number
- SG11202109118XA SG11202109118XA SG11202109118XA SG11202109118XA SG11202109118XA SG 11202109118X A SG11202109118X A SG 11202109118XA SG 11202109118X A SG11202109118X A SG 11202109118XA SG 11202109118X A SG11202109118X A SG 11202109118XA SG 11202109118X A SG11202109118X A SG 11202109118XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- antibody compositions
- treating lupus
- lupus
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962810628P | 2019-02-26 | 2019-02-26 | |
US201962933294P | 2019-11-08 | 2019-11-08 | |
PCT/US2020/019990 WO2020176682A1 (en) | 2019-02-26 | 2020-02-26 | Anti-cd6 antibody compositions and methods for treating lupus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109118XA true SG11202109118XA (en) | 2021-09-29 |
Family
ID=70009403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109118XA SG11202109118XA (en) | 2019-02-26 | 2020-02-26 | Anti-cd6 antibody compositions and methods for treating lupus |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220143140A1 (en) |
EP (1) | EP3930751A1 (en) |
JP (1) | JP2022521973A (en) |
CN (1) | CN113490511A (en) |
AU (1) | AU2020229830A1 (en) |
CA (1) | CA3131299A1 (en) |
MX (1) | MX2021010283A (en) |
SG (1) | SG11202109118XA (en) |
WO (1) | WO2020176682A1 (en) |
ZA (1) | ZA202107077B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230400466A1 (en) * | 2022-05-25 | 2023-12-14 | University Of Houston System | Methods and systems for risk stratification and management of bladder cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998172A (en) * | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
CU22615A1 (en) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED |
CU22584A1 (en) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOCLONAL ANTIBODY THAT RECOGNIZES THE CD6 HUMAN LEUKOCYTARY DIFFERENTIATION ANTIGEN AND ITS USES FOR THE DIAGNOSIS AND TREATMENT OF PSORIASIS |
WO1998043089A1 (en) * | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
AU2007336564B2 (en) | 2006-12-26 | 2012-11-01 | Centro De Inmunologia Molecular | Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-Chronic Lymphocytic Leukaemia |
MX2010010085A (en) * | 2008-03-14 | 2011-03-29 | Biocon Ltd | A monoclonal antibody and a method thereof. |
CN103782173B (en) * | 2011-07-01 | 2018-07-13 | 贝克曼考尔特公司 | Regulatory T-cell and identification obtain and for treating based on immune disorderly method |
WO2015107501A1 (en) * | 2014-01-20 | 2015-07-23 | Ghiggeri Gian Marco | In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis |
US11242401B2 (en) * | 2016-10-21 | 2022-02-08 | Biocon Limited | Monoclonal antibody and a method of use for the treatment of lupus |
-
2020
- 2020-02-26 CA CA3131299A patent/CA3131299A1/en active Pending
- 2020-02-26 AU AU2020229830A patent/AU2020229830A1/en active Pending
- 2020-02-26 MX MX2021010283A patent/MX2021010283A/en unknown
- 2020-02-26 WO PCT/US2020/019990 patent/WO2020176682A1/en unknown
- 2020-02-26 EP EP20714769.5A patent/EP3930751A1/en active Pending
- 2020-02-26 US US17/434,247 patent/US20220143140A1/en active Pending
- 2020-02-26 SG SG11202109118XA patent/SG11202109118XA/en unknown
- 2020-02-26 CN CN202080016831.1A patent/CN113490511A/en active Pending
- 2020-02-26 JP JP2021549772A patent/JP2022521973A/en active Pending
-
2021
- 2021-09-22 ZA ZA2021/07077A patent/ZA202107077B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3131299A1 (en) | 2020-09-03 |
US20220143140A1 (en) | 2022-05-12 |
AU2020229830A1 (en) | 2021-09-16 |
MX2021010283A (en) | 2021-09-30 |
ZA202107077B (en) | 2023-07-26 |
WO2020176682A1 (en) | 2020-09-03 |
CN113490511A (en) | 2021-10-08 |
EP3930751A1 (en) | 2022-01-05 |
JP2022521973A (en) | 2022-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006627B (en) | Methods and compositions for treating cancer | |
IL288914A (en) | Compositions and methods for treating cancer | |
IL286350A (en) | Compositions and methods for treating cancer | |
IL290840A (en) | Compositions and methods for cd123 modification | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
SG11202011849VA (en) | Compositions and methods for treating immune thrombocytopenia | |
IL287961A (en) | Compositions and methods for treating biofilm-related lung conditions | |
IL287982A (en) | Compositions and methods for treating cancer | |
SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
IL280413A (en) | Bismuth-thiol compositions and methods for treating wounds | |
ZA202104870B (en) | Methods and compositions for treating cancer | |
EP4025590A4 (en) | Methods and compositions for treating cancer | |
SG11202012435UA (en) | Compositions and methods for treating cancer | |
ZA202005320B (en) | Anti cd6 antibodies for treating severe asthma | |
EP3965832A4 (en) | Compositions and methods for treating hepatitis b | |
EP3781154A4 (en) | Compositions and methods for treating renal injury | |
IL286153A (en) | Methods and compositions for treating cancer | |
EP3773585A4 (en) | Compositions and methods for treating cancer | |
IL277463A (en) | Compositions and methods for treating pruritus | |
ZA202107077B (en) | Anti-cd6 antibody compositions and methods for treating lupus | |
EP3781945A4 (en) | Compositions and methods for treating endometriosis | |
IL290219A (en) | Compositions and methods for binding antibodies and inhibiting neutralizing antibodies | |
IL285796A (en) | Methods and compositions for treating | |
IL282948A (en) | Compositions and methods for treating cancer | |
EP4077690A4 (en) | Methods and compositions for treating cancer |